WHICH CANCERS
CAN TIL THERAPY TREAT?
TIL therapy is approved for melanoma and actively investigated in multiple other solid tumors. Here is an honest picture of where the evidence stands by cancer type.
Where TIL Therapy Is Most Established
Melanoma has the deepest evidence base and the only current regulatory approval. The FDA's clearance of lifileucel for unresectable or metastatic melanoma in February 2024 came after years of rigorous clinical work targeting patients who had already failed immunotherapy.
โMelanoma led TIL therapy to regulatory approval. Its high mutational burden makes tumor-derived immune cells especially well-positioned to respond.โ
Cancers Currently Under Investigation
Clinical trials are actively investigating TIL therapy across multiple solid tumor types. Evidence levels vary significantly by cancer type.
| Cancer Type | Trial Phase | Evidence Level |
|---|---|---|
| Melanoma | FDA Approved (2024) | Strongest โ regulatory-grade evidence |
| Non-small cell lung cancer | Phase II / III | High โ largest solid tumor trial program outside melanoma |
| Cervical cancer | Phase II | Strong โ compelling early signals; HPV-driven biology favors response |
| Head & neck squamous cell | Phase I / II | Moderate โ specialist center trials in US and Europe |
| Ovarian cancer | Phase I / II | Early โ recurrent or platinum-resistant disease focus |
| Triple-negative breast cancer | Phase I | Early exploration; interest driven by lack of targeted options |
| Bladder cancer | Phase I / II | Under investigation in locally advanced and metastatic settings |
Why Only Solid Tumors?
TIL therapy is anchored in solid tumor biology. Manufacturing starts with tumor tissue โ there needs to be a biopsiable mass to work from. Blood cancers, which do not form localized tissue, fall outside TIL therapy's design. Other cell therapies โ CAR-T, in particular โ are better matched to those.
Realistic Access by Cancer Type
Outside of melanoma, accessing TIL therapy means enrolling in a clinical trial โ involving eligibility criteria, geographic availability, and specific tumor requirements.
Where Active Programs Run
The most active centers are in the United States, United Kingdom, Netherlands, Israel, Denmark, and Australia. Access in many other regions remains genuinely limited.
Trial Phase Matters
Phase I prioritizes safety. Phase II tests effectiveness. Phase III drives regulatory approval. Where a trial sits matters when you are weighing the decision to enroll.
Cancer-Specific TIL Therapy Pages
Read the dedicated TIL therapy pages for specific cancer types.
Frequently Asked Questions
About Cancer Types and TIL Therapy
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Know If TIL Therapy Applies to Your Cancer?
Upload your medical reports for a specialist case review. We will assess your cancer type, treatment history, and current trial availability to give you a realistic picture.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.